In May 2026, the American Heart Association (AHA) formally released the scientific statement "Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update", which updates the 2015 statement. The new statement emphasizes a patient-centered shared decision-making model and further clarifies the application status of several novel drugs, including proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1a), and angiotensin receptor-neprilysin inhibitors (ARNIs), in coronary artery bypass grafting (CABG) patients with relevant indications. This article systematically summarizes and interprets the major recommendations of the statement. In conjunction with the current status of postoperative management after CABG in China, it discusses the potential applicability, implementation barriers, and future research directions of these recommendations, with the aim of providing practical guidance for cardiac surgeons and other clinicians involved in the long-term management of patients after CABG.